Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems
Subhash NE., Prabhu M., Hazarika M., S S., Bhandary SV., Guru BR.
Narrative Review, published in J Biomater Appl (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Biomater Appl (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40811684
- PMCID
- PMC12638462
- DOI
- 10.1177/08853282251369229
- Citations
- 2
Abstract (original English)
The eye is an essential sense organ and drug delivery to the eye is a challenging task due to protective barriers that hinder drug penetration. Over 90 percent of treatments for eye diseases are topical, but frequent administration over extended periods can lead to toxicity and compliance issues. Over the years, extensive research has been aimed at developing drug delivery systems that enhance drug bioavailability at the target site while minimizing side effects. Innovative drug carrier systems have been researched and developed to extend retention time, decrease administration frequency, improve therapeutic efficacy, and ensure biocompatibility. In this article, we delve into the various ocular barriers affecting drug delivery and provide an overview of the utilization of biomaterials and nanotechnology in ocular drug delivery. We explore its applications in the treatment and management of various diseases affecting the anterior segment of the eye.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.